Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $382.7 million, a 3% increase year over year [7] - Adjusted EBITDAre was $73.6 million, up 7% year over year [7] - Normalized FFO increased 172% year over year to $18.6 million, or $0.08 per share [7] Business Line Data and Key Metrics Changes - Same property SHOP NOI increased by 18.5% year over year to $37.4 million [8] - Average monthly rate in the SHOP sector increased by 5.4% year over year, with occupancy rising by 160 basis points to 80.6% [8] - SHOP revenue increased by 6.2% year over year [8] - Medical office and life science portfolio had same property occupancy at 89.9%, down 10 basis points from Q1 [10] Market Data and Key Metrics Changes - The active leasing pipeline in the medical office and life science portfolio includes 691,000 square feet, with 246,000 square feet being new absorption [10] - Weighted average rents for new and renewal leasing activity were 11.5% higher than prior rents [10] Company Strategy and Development Direction - The company is focused on deleveraging its balance sheet through asset sales and refinancing at attractive rates [7] - DHC sold two unencumbered properties for a total of $16.4 million and three additional properties in July for $8.8 million [11] - The company aims to enhance its portfolio with a higher concentration of SHOP assets and stable cash flows from medical office and life science properties [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued recovery of the SHOP segment and the overall positive outlook for the business [10] - The company expects to meet its 2026 debt maturity and anticipates a reduction in leverage towards a target of 6.5 to 7.5 times [20] Other Important Information - The company reduced its 2025 CapEx guidance to $140 million to $160 million, a $10 million reduction from prior guidance [17] - As of July, the company had approximately $292 million in liquidity, including $142 million in unrestricted cash [18] Q&A Session Summary Question: Any notable one-time issues in Q2 2025? - Management indicated that the majority of the NOI benefit came in Q1, with a minor benefit in Q2 from PLGL insurance, approximately $1 million [24][38] Question: CapEx guidance change details? - The change was due to dispositions and a comparison of actual year-to-date spend against the budget [27] Question: Disposition pipeline and future sales? - Management confirmed a mix of assets under PSA and LOI, with additional properties expected to close by year-end or into 2026 [28][30] Question: Performance of Five Star assets compared to others? - Five Star properties have shown improvements due to operational enhancements and capital investments, leading to better performance [31][34] Question: Occupancy targets and growth expectations? - Management expects gradual occupancy growth towards the year-end target of over 82%, influenced by seasonal trends and ongoing dispositions [35]

分组1 - Diversified Healthcare (DHC) reported quarterly funds from operations (FFO) of $0.08 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.03 per share a year ago [1] - The company posted revenues of $382.71 million for the quarter ended June 2025, which was 1.21% below the Zacks Consensus Estimate, compared to $371.39 million in the same quarter last year [2] - The stock has increased approximately 42.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 6.1% [3] 分组2 - The current consensus FFO estimate for the upcoming quarter is $0.10 on revenues of $392.01 million, and for the current fiscal year, it is $0.31 on revenues of $1.57 billion [7] - The Zacks Industry Rank for REIT and Equity Trust - Other is in the top 38% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 1-15319 DIVERSIFIED HEALTHCARE TRUST (Exact Name of Registrant as Specified in Its Charter) 617 - 796 - 8350 (Registrant's Telephone Number, Including Area Code) ...

Financial Results and Supplemental Information SECOND QUARTER 2025 August 4, 2025 Exhibit 99.2 We have also made significant progress in addressing our upcoming debt maturities. Since March 2025, DHC has completed over $343 million of mortgage financings at a weighted average interest rate of 6.54% and used the proceeds, along with cash on hand, to fully redeem our senior unsecured notes due June 2025. DHC also closed a new $150 million secured revolving credit facility, providing added financial flexibilit ...

Group 1 - DHC is classified as a conventional healthcare REIT with significant exposure to volatility in senior housing, indicating a need for nuanced understanding of its current situation [1] - The company is undergoing substantial changes since the onset of COVID-19 in 2020, which may impact its operational and financial performance [1] - The analysis of DHC is part of a broader examination of publicly traded companies across various industries, showcasing the analyst's extensive experience and expertise in financial analysis [1] Group 2 - The analyst possesses CPA qualifications and has experience in evaluating financial statements, which aids in identifying risks and opportunities within companies [1] - The research includes a diverse range of companies, highlighting the analyst's comprehensive approach to market analysis [1]

Core Viewpoint - The article highlights the importance of value investing and identifies Diversified Healthcare Trust (DHC) as a potentially undervalued stock based on various financial metrics [2][4][6]. Company Analysis - Diversified Healthcare Trust (DHC) currently holds a Zacks Rank of 2 (Buy) and a Value grade of A, indicating strong potential for value investors [4]. - DHC's current P/E ratio is 8.12, significantly lower than the industry average P/E of 15.67, suggesting that the stock may be undervalued [4]. - Over the past 52 weeks, DHC's Forward P/E has fluctuated between a high of 45.38 and a low of 5.77, with a median of 8.07, indicating volatility in its valuation [4]. Financial Metrics - DHC has a P/CF ratio of 9.25, which is attractive compared to the industry's average P/CF of 15.55, further supporting the notion of undervaluation [5]. - In the past 12 months, DHC's P/CF has ranged from a high of 37.22 to a low of -189.90, with a median of 5.38, reflecting significant variability in cash flow performance [5]. - The combination of these metrics suggests that DHC is likely undervalued and presents an impressive value opportunity at the moment [6].

Core Insights - Momentum investing focuses on "buying high and selling higher," contrasting with traditional strategies of "buying low and selling high" [1] - Identifying the right entry point for momentum stocks can be challenging, as they may lose momentum if their valuations exceed future growth potential [1] Group 1: Momentum Investing Strategy - Investing in bargain stocks with recent price momentum can be safer, utilizing tools like the Zacks Momentum Style Score to identify potential candidates [2] - The 'Fast-Paced Momentum at a Bargain' screen helps in finding fast-moving stocks that remain attractively priced [2] Group 2: Diversified Healthcare (DHC) Analysis - DHC has shown a four-week price change of 4.7%, indicating growing investor interest [3] - Over the past 12 weeks, DHC's stock has gained 71.5%, demonstrating its ability to deliver positive returns over a longer timeframe [4] - DHC has a beta of 2.45, suggesting it moves 145% higher than the market in either direction, indicating fast-paced momentum [4] Group 3: Valuation and Earnings Estimates - DHC has a Momentum Score of B, suggesting it is an opportune time to invest in the stock [5] - The stock has a Zacks Rank 2 (Buy) due to an upward trend in earnings estimate revisions, which typically attracts more investors [6] - DHC is trading at a Price-to-Sales ratio of 0.57, indicating it is relatively cheap at 57 cents for each dollar of sales [6] Group 4: Additional Opportunities - DHC is not the only stock that meets the 'Fast-Paced Momentum at a Bargain' criteria; other stocks are also available for consideration [7] - There are over 45 Zacks Premium Screens available to help identify winning stock picks based on various investing styles [8]

Core Viewpoint - The article emphasizes the importance of value investing and highlights Diversified Healthcare Trust (DHC) as a strong value stock based on its financial metrics and rankings [2][4][6]. Company Summary - Diversified Healthcare Trust (DHC) currently holds a Zacks Rank of 2 (Buy) and has received an "A" grade in the Value category, indicating strong potential for value investors [3][4]. - DHC is trading at a P/E ratio of 8.57, significantly lower than the industry average P/E of 15.58, suggesting it may be undervalued [4]. - Over the past year, DHC's Forward P/E has fluctuated between a high of 45.38 and a low of 5.77, with a median of 8.06, indicating volatility in its valuation [4]. - The company has a P/CF ratio of 9.45, which is also lower than the industry's average P/CF of 15.43, further supporting the notion of undervaluation [5]. - DHC's P/CF has seen a range from a high of 37.22 to a low of -238.41 over the past year, with a median of -44.33, reflecting significant variability in cash flow metrics [5][6]. - Overall, the financial metrics suggest that DHC is likely undervalued, making it an attractive option for value investors [6].

Investor Presentation June 2025 Overture at Plano 500 Coit Road Plano, TX This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws that are subject to risks and uncertainties. These statements may include words such as "believe", "expect", "anticipate", "intend", "plan", "estimate", "will", "may" and negatives or derivatives of these or similar expressions. These forward-looking statements include, among others ...

Core Viewpoint - Diversified Healthcare Trust (DHC) shows potential as a stock pick due to a recent "golden cross" event, indicating a bullish trend may be forthcoming [1][2]. Technical Analysis - A "golden cross" occurs when a stock's short-term moving average (50-day) crosses above its long-term moving average (200-day), suggesting a bullish breakout [2]. - The successful golden cross event consists of three stages: a price decline bottoming out, the shorter moving average crossing above the longer one, and maintaining upward momentum [3]. Performance Metrics - DHC shares have increased by 14.7% over the past four weeks, indicating positive momentum [4]. - The company holds a 2 (Buy) rating on the Zacks Rank, suggesting strong potential for further breakout [4]. Earnings Outlook - DHC's earnings outlook for the current quarter is positive, with one upward revision and no downward revisions in the past 60 days, leading to an increase in the Zacks Consensus Estimate [4]. - The combination of the technical indicator and positive earnings estimates makes DHC a candidate for investors' watchlists [6].